|
|
|
|
LEADER |
04613nam a2201033Ia 4500 |
001 |
10.1002-hbm.25414 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 10659471 (ISSN)
|
245 |
1 |
0 |
|a Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer's disease: A longitudinal study
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/hbm.25414
|
520 |
3 |
|
|a This study is an observational study that takes the existing longitudinal data from Alzheimer's disease Neuroimaging Initiative to examine the spatial correlation map of hippocampal subfield atrophy with CSF biomarkers and cognitive decline in the course of AD. This study included 421 healthy controls (HC), 557 patients of stable mild cognitive impairment (s-MCI), 304 Alzheimer's Disease (AD) patients, and 241 subjects who converted to be AD from MCI (c-MCI), and 6,525 MRI scans in a period from 2004 to 2019. Our findings revealed that all the hippocampal subfields showed their accelerated atrophy rate from cognitively normal aging to stable MCI and AD. The presubiculum, dentate gyrus, and fimbria showed greater atrophy beyond the whole hippocampus in the HC, s-MCI, and AD groups and corresponded to a greater decline of memory and attention in the s-MCI group. Moreover, the higher atrophy rates of the subiculum and CA2/3, CA4 were also associated with a greater decline in attention in the s-MCI group. Interestingly, patients with c-MCI showed that the presubiculum atrophy was associated with CSF tau levels and corresponded to the onset age of AD and a decline in attention in patients with c-MCI. These spatial correlation findings of the hippocampus suggested that the hippocampal subfields may not be equally impacted by normal aging, MCI, and AD, and their atrophy was selectively associated with declines in specific cognitive domains. The presubiculum atrophy was highlighted as a surrogate marker for the AD prognosis along with tau pathology and attention decline. © 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
|
650 |
0 |
4 |
|a aged
|
650 |
0 |
4 |
|a Aged
|
650 |
0 |
4 |
|a Aged, 80 and over
|
650 |
0 |
4 |
|a aging
|
650 |
0 |
4 |
|a Aging
|
650 |
0 |
4 |
|a Alzheimer disease
|
650 |
0 |
4 |
|a Alzheimer disease
|
650 |
0 |
4 |
|a Alzheimer Disease
|
650 |
0 |
4 |
|a amygdala
|
650 |
0 |
4 |
|a amyloid beta protein[1-42]
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a atrophy
|
650 |
0 |
4 |
|a Atrophy
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a Biomarkers
|
650 |
0 |
4 |
|a brain atrophy
|
650 |
0 |
4 |
|a brain size
|
650 |
0 |
4 |
|a cerebrospinal fluid
|
650 |
0 |
4 |
|a cognition
|
650 |
0 |
4 |
|a cognitive defect
|
650 |
0 |
4 |
|a Cognitive Dysfunction
|
650 |
0 |
4 |
|a cognitive function
|
650 |
0 |
4 |
|a comparative study
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a CSF tau pathology
|
650 |
0 |
4 |
|a dentate gyrus
|
650 |
0 |
4 |
|a diagnostic imaging
|
650 |
0 |
4 |
|a disease exacerbation
|
650 |
0 |
4 |
|a disease exacerbation
|
650 |
0 |
4 |
|a Disease Progression
|
650 |
0 |
4 |
|a executive function
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a follow up
|
650 |
0 |
4 |
|a granule cell
|
650 |
0 |
4 |
|a hippocampal subfields
|
650 |
0 |
4 |
|a hippocampus
|
650 |
0 |
4 |
|a Hippocampus
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a language
|
650 |
0 |
4 |
|a Longitudinal Studies
|
650 |
0 |
4 |
|a longitudinal study
|
650 |
0 |
4 |
|a longitudinal study
|
650 |
0 |
4 |
|a Magnetic Resonance Imaging
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a memory
|
650 |
0 |
4 |
|a mild cognitive impairment
|
650 |
0 |
4 |
|a Mini Mental State Examination
|
650 |
0 |
4 |
|a molecular layer
|
650 |
0 |
4 |
|a MRI
|
650 |
0 |
4 |
|a neuroimaging
|
650 |
0 |
4 |
|a neuropsychological test
|
650 |
0 |
4 |
|a nuclear magnetic resonance imaging
|
650 |
0 |
4 |
|a observational study
|
650 |
0 |
4 |
|a onset age
|
650 |
0 |
4 |
|a pathology
|
650 |
0 |
4 |
|a pathophysiology
|
650 |
0 |
4 |
|a phosphoprotein
|
650 |
0 |
4 |
|a physiology
|
650 |
0 |
4 |
|a positron emission tomography
|
650 |
0 |
4 |
|a priority journal
|
650 |
0 |
4 |
|a protein cerebrospinal fluid level
|
650 |
0 |
4 |
|a Rey auditory verbal learning test
|
650 |
0 |
4 |
|a right hemisphere
|
650 |
0 |
4 |
|a subiculum
|
650 |
0 |
4 |
|a tau protein
|
650 |
0 |
4 |
|a the onset of AD
|
650 |
0 |
4 |
|a three-dimensional imaging
|
650 |
0 |
4 |
|a trail making test
|
650 |
0 |
4 |
|a very elderly
|
700 |
1 |
|
|a Liu, C.
|e author
|
700 |
1 |
|
|a Liu, G.
|e author
|
700 |
1 |
|
|a Qiu, A.
|e author
|
700 |
1 |
|
|a the Alzheimer's Disease Neuroimaging Initiative
|e author
|
773 |
|
|
|t Human Brain Mapping
|